Misplaced Pages

OPC-64005

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Experimental antidepressant drug Pharmaceutical compound
OPC-64005
Clinical data
Other namesOPC64005
Routes of
administration		Oral
Drug classSerotonin–norepinephrine–dopamine reuptake inhibitor (triple reuptake inhibitor)

OPC-64005 is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), or "triple reuptake inhibitor" (TRI), which is under development for the treatment of major depressive disorder. It was also under development for the treatment of attention deficit hyperactivity disorder (ADHD), but development for this indication was discontinued. It is taken by mouth.

As of December 2022, OPC-64005 is in phase 2 clinical trials for major depressive disorder. It reached phase 2 clinical trials for ADHD prior to the discontinuation of its development for this use. It completed a phase 2 clinical trial for ADHD comparing it with placebo and atomoxetine, but the results of this trial were not disclosed. The drug is under development by Otsuka Pharmaceutical. It is a small molecule, but its chemical structure does not appear to have been disclosed.

References

  1. ^ "OPC 64005". AdisInsight. 7 December 2022. Retrieved 22 October 2024.
  2. ^ "Delving into the Latest Updates on OPC-64005 with Synapse". Synapse. 17 October 2024. Retrieved 22 October 2024.
  3. Rodríguez-Lavado J, Alarcón-Espósito J, Mallea M, Lorente A (August 2022). "A New Paradigm Shift in Antidepressant Therapy: From Dual-action to Multitarget-directed Ligands". Curr Med Chem. 29 (29): 4896–4922. doi:10.2174/0929867329666220317121551. PMID 35301942.
  4. Nageye F, Cortese S (July 2019). "Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD". Expert Rev Neurother. 19 (7): 707–717. doi:10.1080/14737175.2019.1628640. PMID 31167583.
  5. Williams OC, Prasad S, McCrary A, Jordan E, Sachdeva V, Deva S, Kumar H, Mehta J, Neupane P, Gupta A (May 2023). "Adult attention deficit hyperactivity disorder: a comprehensive review". Ann Med Surg (Lond). 85 (5): 1802–1810. doi:10.1097/MS9.0000000000000631. PMC 10205222. PMID 37228994.
Monoamine reuptake inhibitors
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: